Meridian says no to Gull at $3 a share:
This article was originally published in Clinica
Meridian Diagnostics has lowered its earlier offer of $3 a share for Fresenius subsidiary Gull Laboratories, based on Gull's results for the second quarter. According to Gull's president and CEO, Dr Silke Humberg, Meridian, Gull and Fresenius are still willing to complete the deal and are in negotiations to fix a price.
You may also be interested in...
As the first emergency use authorization is granted, Pfizer and Moderna stand accused of neglecting poorer nations as wealthy countries snap up early access to COVID-19 vaccines.
The FDA has released final guidance on “Formal Meetings Between FDA and ANDA Applicants of Complex Products Under GDUFA” for the industry. The guidance brings clarity and aims at facilitating product development meetings between the FDA and the ANDA applicants for complex products.
By handing out free supplements to the clinically vulnerable, the UK government is effectively endorsing the use of vitamin D to reduce the risk and/or severity of COVID-19, although it says more research is needed.